Skip to main content
Erschienen in: Die Onkologie 4/2022

14.03.2022 | Akute myeloische Leukämie | CME

Infektionsmanagement in der Hämatologie und Onkologie

Verantwortungsvoller Einsatz von Antiinfektiva

verfasst von: Dr. med. Annika Yanina Classen, PD Dr. med. Michael Sandherr, Prof. Dr. med. Jörg Janne Vehreschild, Prof. Dr. med. Marie von Lilienfeld-Toal

Erschienen in: Die Onkologie | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hämatologische und onkologische Patienten haben aufgrund der durch die Grunderkrankung bestehenden oder therapieassoziierten Immunsuppression oftmals ein deutlich erhöhtes Infektionsrisiko. Unter Berücksichtigung weltweit zunehmender antimikrobieller Resistenzen und negativer mit der Antibiotikatherapie assoziierter Effekte sollte der angemessene und leitliniengerechte Einsatz von Antiinfektiva auch in diesem Bereich gefördert werden. Die Indikation zur antibakteriellen Prophylaxe sollte streng gestellt werden. Die Infektionsdiagnostik sowie das therapeutische Management unterscheiden sich je nach Ausmaß der erwarteten Immunsuppression und nach vorliegenden patientenindividuellen Risikofaktoren.
Literatur
1.
Zurück zum Zitat Schuts EC, Hulscher M, Mouton JW et al (2016) Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis 16(7):847–856PubMedCrossRef Schuts EC, Hulscher M, Mouton JW et al (2016) Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis 16(7):847–856PubMedCrossRef
3.
Zurück zum Zitat Molina J, Noguer M, Lepe JA et al (2019) Clinical impact of an educational antimicrobial stewardship program associated with infectious diseases consultation targeting patients with cancer: Results of a 9-year quasi-experimental study with an interrupted time-series analysis. J Infect 79(3):206–211PubMedCrossRef Molina J, Noguer M, Lepe JA et al (2019) Clinical impact of an educational antimicrobial stewardship program associated with infectious diseases consultation targeting patients with cancer: Results of a 9-year quasi-experimental study with an interrupted time-series analysis. J Infect 79(3):206–211PubMedCrossRef
5.
Zurück zum Zitat Willmann M, Vehreschild M, Biehl LM et al (2019) Distinct impact of antibiotics on the gut microbiome and resistome: a longitudinal multicenter cohort study. BMC Biol 17(1):76PubMedPubMedCentralCrossRef Willmann M, Vehreschild M, Biehl LM et al (2019) Distinct impact of antibiotics on the gut microbiome and resistome: a longitudinal multicenter cohort study. BMC Biol 17(1):76PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Vehreschild MJ, Liss BJ, Cornely OA (2013) Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 41(5):1049–1050PubMedCrossRef Vehreschild MJ, Liss BJ, Cornely OA (2013) Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 41(5):1049–1050PubMedCrossRef
7.
Zurück zum Zitat Vehreschild MJ, Weitershagen D, Biehl LM et al (2014) Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis. Biol Blood Marrow Transplant 20(6):823–828PubMedCrossRef Vehreschild MJ, Weitershagen D, Biehl LM et al (2014) Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis. Biol Blood Marrow Transplant 20(6):823–828PubMedCrossRef
8.
Zurück zum Zitat Haak BW, Littmann ER, Chaubard JL et al (2018) Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood 131(26):2978–2986PubMedPubMedCentral Haak BW, Littmann ER, Chaubard JL et al (2018) Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood 131(26):2978–2986PubMedPubMedCentral
9.
Zurück zum Zitat de Jong E, van Oers JA, Beishuizen A et al (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16(7):819–827PubMedCrossRef de Jong E, van Oers JA, Beishuizen A et al (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16(7):819–827PubMedCrossRef
10.
Zurück zum Zitat Tsikala-Vafea M, Belani N, Vieira K, Khan H, Farmakiotis D (2021) Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Int J Infect Dis 106:142–154PubMedCrossRef Tsikala-Vafea M, Belani N, Vieira K, Khan H, Farmakiotis D (2021) Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Int J Infect Dis 106:142–154PubMedCrossRef
11.
Zurück zum Zitat Döhner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447PubMedPubMedCentralCrossRef Döhner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Classen AY, Henze L, von Lilienfeld-Toal M et al (2021) Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol 100(6):1603–1620PubMedPubMedCentralCrossRef Classen AY, Henze L, von Lilienfeld-Toal M et al (2021) Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol 100(6):1603–1620PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Vehreschild JJ, Böhme A, Cornely OA et al (2014) Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Ann Oncol 25(9):1709–1718PubMedCrossRef Vehreschild JJ, Böhme A, Cornely OA et al (2014) Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Ann Oncol 25(9):1709–1718PubMedCrossRef
14.
Zurück zum Zitat Mellinghoff SC, Panse J, Alakel N et al (2018) Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol 97(2):197–207PubMedCrossRef Mellinghoff SC, Panse J, Alakel N et al (2018) Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol 97(2):197–207PubMedCrossRef
15.
Zurück zum Zitat Maertens JA, Girmenia C, Brüggemann RJ et al (2018) European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother 73(12):3221–3230PubMed Maertens JA, Girmenia C, Brüggemann RJ et al (2018) European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother 73(12):3221–3230PubMed
16.
Zurück zum Zitat Henze L, Buhl C, Sandherr M et al (2022) Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus. Ann Hematol. https://doi.org/10.1007/s00277-021-04746-yPubMedPubMedCentralCrossRef Henze L, Buhl C, Sandherr M et al (2022) Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus. Ann Hematol. https://​doi.​org/​10.​1007/​s00277-021-04746-yPubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Heinz WJ, Buchheidt D, Christopeit M et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96(11):1775–1792PubMedPubMedCentralCrossRef Heinz WJ, Buchheidt D, Christopeit M et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96(11):1775–1792PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Lilienfeld-Toal M van. Infektionsprophylaxe und -therapie. In: Honecker, Claßen, Preiß, Dornoff (Hrsg) Taschenbuch Hämatologie und Onkologie. Interdisziplinäre Empfehlungen zur Therapie 2022/23. Zuckerschwerdt Verlag Lilienfeld-Toal M van. Infektionsprophylaxe und -therapie. In: Honecker, Claßen, Preiß, Dornoff (Hrsg) Taschenbuch Hämatologie und Onkologie. Interdisziplinäre Empfehlungen zur Therapie 2022/23. Zuckerschwerdt Verlag
19.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051PubMedCrossRef Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051PubMedCrossRef
20.
Zurück zum Zitat Pagano L, Caira M, Nosari A et al (2011) Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e‑Chart Registry. Arch Intern Med 171(16):1502–1503PubMedCrossRef Pagano L, Caira M, Nosari A et al (2011) Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e‑Chart Registry. Arch Intern Med 171(16):1502–1503PubMedCrossRef
21.
Zurück zum Zitat Maschmeyer G, Link H, Hiddemann W et al (1994) Empirical antimicrobial therapy in neutropenic patients. Results of a multicenter study by the Infections in Hematology Study Group of the Paul Ehrlich Society. Med Klin 89(3):114–123 Maschmeyer G, Link H, Hiddemann W et al (1994) Empirical antimicrobial therapy in neutropenic patients. Results of a multicenter study by the Infections in Hematology Study Group of the Paul Ehrlich Society. Med Klin 89(3):114–123
22.
Zurück zum Zitat von Lilienfeld-Toal M, Berger A, Christopeit M et al (2016) Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. Eur J Cancer 67:200–212CrossRef von Lilienfeld-Toal M, Berger A, Christopeit M et al (2016) Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. Eur J Cancer 67:200–212CrossRef
23.
Zurück zum Zitat Maschmeyer G, Carratalà J, Buchheidt D et al (2015) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 26(1):21–33PubMedCrossRef Maschmeyer G, Carratalà J, Buchheidt D et al (2015) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 26(1):21–33PubMedCrossRef
Metadaten
Titel
Infektionsmanagement in der Hämatologie und Onkologie
Verantwortungsvoller Einsatz von Antiinfektiva
verfasst von
Dr. med. Annika Yanina Classen
PD Dr. med. Michael Sandherr
Prof. Dr. med. Jörg Janne Vehreschild
Prof. Dr. med. Marie von Lilienfeld-Toal
Publikationsdatum
14.03.2022
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 4/2022
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-022-01120-z

Weitere Artikel der Ausgabe 4/2022

Die Onkologie 4/2022 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.